Clearmind Medicine (US:CMND) Globenewswire·2025-10-28 12:08Core Insights - Clearmind Medicine Inc. is participating in a webinar focused on women in psychedelic leadership, highlighting its commitment to advancing psychedelic medicine [1][2] - The CEO, Dr. Adi Zuloff-Shani, will share insights on the company's strategic direction and the broader psychedelic landscape [2][3] Company Overview - Clearmind is a clinical-stage biotech company dedicated to developing novel neuroplastogen-derived therapeutics for under-treated health issues, including alcohol use disorder, cocaine addiction, and obesity [1][4] - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents as needed [5] Event Details - The webinar titled "Women in Psychedelic Leadership: Driving Innovation & Governance" is scheduled for October 29, 2025, at 9:00 AM PT/noon ET, and will be accessible online [1][2][3] - Registration for the event is available through Eventbrite, inviting investors, researchers, and stakeholders to participate [3]